CION Ameerpet
NLPHL is a rare, usually slow-growing subtype of Hodgkin lymphoma defined by CD20-positive "popcorn" cells. This guide explains how it differs from classical Hodgkin lymphoma, how it is diagnosed, and how CION's lymphoma team plans nlphl treatment.
NLPHL — nodular lymphocyte-predominant Hodgkin lymphoma — is a rare and distinct type of Hodgkin lymphoma. It accounts for only around 5% of all Hodgkin lymphoma cases, which is why it is far less familiar than the classical form. Despite the shared "Hodgkin" name, NLPHL has its own biology, its own diagnostic footprint and its own treatment approach — so getting the label exactly right genuinely matters.
The defining feature of NLPHL is the tumour cell. Instead of the Reed-Sternberg cells seen in classical Hodgkin lymphoma, NLPHL contains characteristic "popcorn" cells (also called LP cells) that are strongly CD20-positive and usually CD30- and CD15-negative. This CD20 positivity is not just an academic detail — it opens up treatment options that target the CD20 marker directly. NLPHL is typically slow-growing (indolent), often shows up as a single enlarged lymph node in the neck, armpit or groin, and is frequently caught at an early stage.
This page explains how NLPHL differs from the classical form, how it is diagnosed, what lymphocyte predominant hodgkin lymphoma treatment involves, and the outlook. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
NLPHL makes up only about 5% of all Hodgkin lymphoma cases, and its tumour "popcorn" (LP) cells are CD20-positive — unlike the CD20-negative Reed-Sternberg cells of classical Hodgkin lymphoma. This single difference in a surface marker is one reason NLPHL is treated as a separate entity, and why therapies targeting CD20 can be considered. (Source: WHO haematolymphoid classification, as referenced in NCCN and ESMO Hodgkin lymphoma guidelines.)
Both are types of Hodgkin lymphoma, but they differ at the level of the tumour cell — and those differences shape the tests and the treatment. Understanding which one you have is the first step.
| Feature | NLPHL | Classical Hodgkin lymphoma |
|---|---|---|
| Tumour cell | "Popcorn" / LP cells | Reed-Sternberg cells |
| CD20 marker | Positive | Usually negative |
| CD30 / CD15 | Usually negative | Positive |
| How common | Rare (~5% of Hodgkin cases) | The large majority of cases |
| Typical behaviour | Often indolent (slow); often early-stage | Variable; can be more aggressive |
General guide only; features vary by individual. The diagnosis is decided by an expert haematopathologist on tissue, not by a scan. Classification and marker patterns follow the WHO classification and NCCN/ESMO guidance. Read more about the classical form and its subtypes, including nodular sclerosis Hodgkin lymphoma.
NLPHL usually announces itself quietly — which is exactly why expert assessment matters.
The most common presentation is a single, painless lymph node that slowly enlarges in the neck, armpit or groin. The so-called "B symptoms" — fever, drenching night sweats and unexplained weight loss — are relatively uncommon in NLPHL compared with the classical form.
Because NLPHL can mimic both classical Hodgkin lymphoma and certain B-cell lymphomas under the microscope, an accurate diagnosis depends on an expert haematopathologist and a full immunohistochemistry panel. This is where a specialist centre makes the biggest difference.
Because NLPHL is often indolent and CD20-positive, the right plan can range from careful monitoring to radiation or CD20-targeted therapy. Over-treating an indolent tumour, or under-treating a more advanced one, are both risks a specialist lymphoma centre is set up to avoid.
NLPHL can relapse years later, and a minority can transform into a more aggressive lymphoma. Structured, long-term follow-up with an experienced team is part of caring for NLPHL properly — see our lymphoma doctors in Hyderabad.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just been told you have NLPHL, want to confirm the diagnosis, or need a second opinion before treatment? CION's lymphoma team is here to help.
Confirming NLPHL — and separating it from its look-alikes — takes a careful, step-by-step pathway. CION delivers the biopsy coordination, pathology review, imaging and staging directly.
The single most important step is usually an excisional biopsy — removing an entire affected lymph node rather than taking a small needle sample. This matters because the diagnosis of NLPHL depends on both the pattern of the whole node and the appearance of the LP cells within it; a needle biopsy alone is often not enough to tell NLPHL apart from classical Hodgkin lymphoma or a B-cell lymphoma.
An expert haematopathologist examines the tissue and runs an immunohistochemistry panel. The hallmark of NLPHL is CD20-positive "popcorn" LP cells that are usually CD30- and CD15-negative — the mirror image of classical Hodgkin lymphoma. Getting these markers right is what confirms the diagnosis. CION arranges the full panel and expert review as standard, in line with NCCN and ESMO recommendations.
Once NLPHL is confirmed, a PET-CT scan maps how much disease is present and where — which determines the stage and steers treatment. In selected cases a bone-marrow examination is added. CION performs the imaging and staging in-house and reviews the results at the tumour board.
For NLPHL, an excisional biopsy — removing a whole lymph node — is generally preferred over a needle sample. The reason is that NLPHL is diagnosed from both the overall architecture of the node and the CD20-positive LP "popcorn" cells within it, and a small needle core often cannot show enough to separate NLPHL from classical Hodgkin lymphoma or a B-cell lymphoma. (Source: NCCN and ESMO Hodgkin lymphoma diagnostic guidance.)
Because NLPHL is usually indolent and CD20-positive, treatment is carefully matched to the stage and the amount of disease. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. For specific drug names and full treatment pathways, our Lymphoma Treatment in Hyderabad page goes deeper. The main building blocks are:
For selected early-stage NLPHL — particularly where the diagnostic excision has removed all visible disease — careful active surveillance may be the right choice. This means regular clinical review and imaging rather than immediate treatment, avoiding side effects while the disease is quiet, with a clear plan to step in if anything changes.
Localised, early-stage NLPHL is often treated with involved-site radiation therapy. CION delivers precision radiation — IMRT and IGRT — directly, shaping the beam to the affected area while sparing surrounding healthy tissue. For many early-stage patients this alone can achieve excellent, durable control.
More advanced or bulky NLPHL may be treated with chemotherapy, sometimes combined with an anti-CD20 monoclonal antibody — an option that is available precisely because the LP cells carry the CD20 marker. CION's medical oncology and haematology team delivers systemic therapy and antibody treatment directly. Where high-dose therapy with a stem-cell transplant is needed in selected relapsed cases, it is coordinated through accredited partner facilities, not delivered in-house.
Because NLPHL can relapse late or occasionally transform, structured long-term follow-up is part of the plan. Any new or growing node is reviewed promptly, with options considered along similar lines to relapsed Hodgkin lymphoma when relevant.
NLPHL generally carries a favourable outlook, especially when found at an early stage. Many published series report long-term survival in the region of 80–90% or higher for early-stage disease — figures broadly in line with overall Hodgkin lymphoma survival (Hodgkin lymphoma survival is often quoted around 80–90%, considerably higher than more aggressive lymphomas such as DLBCL at roughly 60–70% in published series). These are general, published, attributed figures and vary considerably by individual, depending on stage, age and how the disease behaves.
Two features shape the long view. NLPHL can relapse years after treatment, and a small minority can transform into a more aggressive B-cell lymphoma — which is why long-term follow-up is built into care. For a fuller breakdown of survival across the disease, see Hodgkin lymphoma survival & cure rates and the symptoms to watch for. Survival figures are drawn from published NCCN/ESMO-referenced series; your team can explain what they mean for your specific situation.
NLPHL can affect people at any age, but it is often diagnosed in younger and middle-aged adults, and it is somewhat more common in men. For younger patients, balancing effective control against the long-term side effects of treatment is a central part of planning — a theme we explore for Hodgkin lymphoma in young adults. Where a diagnosis is made around family planning or during pregnancy, care is coordinated closely so that both mother and baby are protected. In every case, the plan is individualised and reviewed by the tumour board.
NLPHL is uncommon and easy to confuse with other lymphomas, so a second opinion is especially worthwhile in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if your biopsy has not yet been reviewed by an expert haematopathologist.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.NLPHL is a rare and distinct type of Hodgkin lymphoma, making up roughly 5% of all Hodgkin lymphoma cases. It is set apart from classical Hodgkin lymphoma by the type of tumour cell involved — instead of the classic Reed-Sternberg cells, NLPHL contains characteristic "popcorn" cells (also called LP cells) that are CD20-positive and typically CD30-negative and CD15-negative. NLPHL tends to grow slowly, is often found at an early stage, and usually behaves in an indolent (slow) manner. Because its biology overlaps with certain B-cell lymphomas, an accurate diagnosis by an expert haematopathologist is essential before any treatment decision. Learn more on our Lymphoma hub.
The two differ at the level of the tumour cell and, often, in how they behave. Classical Hodgkin lymphoma contains Reed-Sternberg cells that are CD30-positive and CD15-positive but usually CD20-negative. NLPHL instead contains "popcorn" (LP) cells that are strongly CD20-positive and generally CD30/CD15-negative. NLPHL is far less common, tends to affect the lymph nodes in the neck, armpit or groin, often presents at an early stage, and typically follows a slower, more indolent course. These differences matter because they change which tests confirm the diagnosis and which treatment approaches are appropriate. Distinguishing the two accurately, per NCCN and ESMO guidance, is a job for a specialist haematopathologist.
Because NLPHL is usually slow-growing, treatment is tailored to the stage and how much disease is present. For early-stage disease that has been completely removed by the diagnostic excision, careful active surveillance (watch-and-wait monitoring) may be appropriate. Localised early-stage NLPHL is often treated with involved-site radiation therapy (IMRT), which CION delivers directly. More advanced or bulky disease may be treated with chemotherapy, sometimes combined with an anti-CD20 monoclonal antibody — used because the LP cells are CD20-positive. Every case is reviewed by our multidisciplinary tumour board first. For specific drug regimens and full pathways, see our Lymphoma Treatment in Hyderabad page.
CD20 is a protein found on the surface of the "popcorn" LP cells that characterise NLPHL — and this is one of the key features that separates it from classical Hodgkin lymphoma, where the tumour cells are usually CD20-negative. Testing for CD20 (along with CD30, CD15 and other markers) on the biopsy tissue is central to confirming the diagnosis. It also has practical treatment relevance: because the tumour cells carry CD20, therapies that target this marker — such as an anti-CD20 monoclonal antibody — can be considered as part of the plan for selected patients. CION arranges the full immunohistochemistry panel needed to characterise NLPHL, with review by an expert haematopathologist, in line with NCCN and ESMO recommendations.
Diagnosis begins with a biopsy — usually an excisional biopsy that removes an entire affected lymph node, because the architecture of the node and the pattern of the LP cells both need to be assessed. A needle biopsy alone is often not enough. An expert haematopathologist then examines the tissue and runs an immunohistochemistry panel (looking at CD20, CD30, CD15 and other markers) to confirm the "popcorn" LP cells and rule out mimics such as classical Hodgkin lymphoma or certain B-cell lymphomas. Staging then uses a PET-CT scan and, in some cases, a bone-marrow examination. CION delivers the biopsy coordination, pathology review, PET-CT and staging directly. Read more on the Hodgkin lymphoma overview.
NLPHL generally carries a favourable outlook, especially when it is diagnosed at an early stage — many published series report long-term survival in the region of 80–90% or higher for early-stage disease, a figure often quoted alongside overall Hodgkin lymphoma survival. Individual outcomes vary considerably by stage, age and how the disease behaves, so these figures are general and not a prediction for any one person. A small proportion of NLPHL can, over time, transform into a more aggressive lymphoma, which is one reason long-term follow-up matters even after successful treatment. For survival detail across Hodgkin lymphoma, see Hodgkin lymphoma survival & cure rates. Figures are drawn from published NCCN/ESMO-referenced series and vary by individual.
Yes — two things are worth understanding. First, NLPHL can relapse (come back) even years after treatment, which is why long-term follow-up with a specialist is important; relapses are often still very treatable. Second, in a minority of cases NLPHL can transform into a more aggressive B-cell lymphoma over time. Regular monitoring is designed to catch either situation early, when treatment options are broadest. If disease does return, the plan is reviewed by CION's tumour board and options are discussed in the context of what was used before — similar in principle to the approach outlined for relapsed Hodgkin lymphoma. A prompt review of any new or growing lymph node is always the safest step.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.